Nonetheless despite this major limitation, in the clinic a mutation in MSH2 or MLH1 in a tumor is generally managed in the same way as a finding of MSI by MSI testing and both contribute to a high tumor mutation burden in CRC. The gene discussed is MLH1; the disease is neoplasm.